|
US7244577B2
(en)
*
|
1997-04-15 |
2007-07-17 |
Merck & Co., Inc. |
Method of screening for modulator of LRP5 activity
|
|
US6770461B1
(en)
|
1998-10-23 |
2004-08-03 |
Genome Therapeutics Corporation |
High bone mass gene of 11q13.3
|
|
US6780609B1
(en)
|
1998-10-23 |
2004-08-24 |
Genome Therapeutics Corporation |
High bone mass gene of 1.1q13.3
|
|
US6699466B1
(en)
*
|
1999-08-05 |
2004-03-02 |
Research Corporation Technologies, Inc. |
IL-16 antagonist peptides and DNA encoding the peptides
|
|
FR2798138B1
(fr)
*
|
1999-09-03 |
2004-05-21 |
Centre Nat Rech Scient |
Clonage, expression et caracterisation du gene spg4 responsable de la forme la plus frequente de paraplegie spastique autosomique dominante
|
|
IL151904A0
(en)
*
|
2000-04-05 |
2003-04-10 |
Genome Therapeutics Corp |
THE HIGH BONE MASS GENE OF 11q13.3
|
|
DE60129433T2
(de)
*
|
2000-05-26 |
2008-04-17 |
Oscient Pharmaceuticals Corp., Waltham |
Regulation des lipidniveaus über die gene zmax1 oder hbm
|
|
US7179462B2
(en)
|
2000-06-02 |
2007-02-20 |
University Of Connecticut Health Center |
α (2) macroglobulin receptor as a heat shock protein receptor and uses thereof
|
|
US7186515B1
(en)
|
2000-06-02 |
2007-03-06 |
University Of Connecticut Health Center |
Alpha(2) macroglobulin receptor as a heat shock protein receptor and uses thereof
|
|
EP1286693A4
(en)
|
2000-06-02 |
2005-07-13 |
Univ Connecticut Health Ct |
COMPLEXES OF ALPHA (2) MACROGLOBULIN AND ANTIGENIC MOLECULES FOR USE IN IMMUNOTHERAPY
|
|
EP1313753A4
(en)
*
|
2000-08-18 |
2004-09-15 |
Proskelia |
REGULATORY GENE AND SYSTEM FOR USE IN THE DIAGNOSIS AND TREATMENT OF OSTEOPOROSIS
|
|
WO2002074906A2
(en)
*
|
2001-03-16 |
2002-09-26 |
Eli Lilly And Company |
Lp mammalian proteins; related reagents
|
|
US20040221326A1
(en)
*
|
2001-05-11 |
2004-11-04 |
Philip Babij |
Transgenic animal model of bone mass modulation
|
|
WO2002092000A2
(en)
|
2001-05-11 |
2002-11-21 |
Genome Therapeutics Corporation |
Hbm variants that modulate bone mass and lipid levels
|
|
US7514594B2
(en)
*
|
2001-05-11 |
2009-04-07 |
Wyeth |
Transgenic animal model of bone mass modulation
|
|
US20040038860A1
(en)
|
2002-05-17 |
2004-02-26 |
Allen Kristina M. |
Reagents and methods for modulating dkk-mediated interactions
|
|
JP2005512508A
(ja)
*
|
2001-05-17 |
2005-05-12 |
ゲノム セラピューティックス コーポレーション |
Ｄｋｋ媒介性相互作用を変調する試薬および方法
|
|
CN1635896A
(zh)
|
2001-08-20 |
2005-07-06 |
康涅狄格大学健康中心 |
包含用于治疗癌症及感染性疾病的热休克蛋白或α2－巨球蛋白的组合物制备方法
|
|
GB2381790A
(en)
*
|
2001-09-26 |
2003-05-14 |
Glaxo Group Ltd |
LDL-receptor polypeptides
|
|
JP2005220022A
(ja)
*
|
2002-03-08 |
2005-08-18 |
Anges Mg Inc |
Ｗｎｔの新規作用、及び、疾患治療への応用
|
|
US7169559B2
(en)
*
|
2002-05-13 |
2007-01-30 |
Fonterra Corporate Research and Development Ltd. |
LDL receptor-related proteins 1 and 2 and treatment of bone or cartilage conditions
|
|
US20030219793A1
(en)
*
|
2002-10-04 |
2003-11-27 |
Carulli John P. |
High bone mass gene of 11q13.3
|
|
WO2005049797A2
(en)
|
2003-11-17 |
2005-06-02 |
Merck & Co., Inc. |
Cynomolgus monkey dickkopf-4, nucleotides encoding same, and uses thereof
|
|
US7622553B2
(en)
|
2003-11-17 |
2009-11-24 |
Merck & Co., Inc. |
Rhesus monkey dickkopf-1, nucleotides encoding same, and uses thereof
|
|
WO2005048913A2
(en)
*
|
2003-11-24 |
2005-06-02 |
Gunnar Westin |
Mutant lrp5/6 wnt-signaling receptors in cancer diagnosis, prognosis and treatment
|
|
EP2566892B1
(en)
|
2010-05-06 |
2017-12-20 |
Novartis AG |
Compositions and methods of use for therapeutic low density lipoprotein-related protein 6 (lrp6) antibodies
|
|
PH12012502193A1
(en)
|
2010-05-06 |
2021-08-09 |
Novartis Ag |
Compositions and methods of use for therapeutic low density lipoprotein - related protein 6 (lrp6) multivalent antibodies
|
|
ES2666856T3
(es)
|
2011-11-04 |
2018-05-08 |
Novartis Ag |
Proteína 6 relacionada con lipoproteínas de baja densidad (LRP6) - constructos extensores de la vida media
|
|
EP3630816B1
(en)
|
2017-05-31 |
2024-03-20 |
Boehringer Ingelheim International GmbH |
Polypeptides antagonizing wnt signaling in tumor cells
|